Biogen Inc. (BIIB) Earnings Call Transcripts

28 earnings calls from January 2020 to October 28, 2026

NASDAQ US Health Care Biotechnology

Biogen Inc.'s Latest Earnings Call - Q3 FY2026

In the third quarter of 2026, Biogen Inc. reported total revenue of $2.8 billion, reflecting an 11% year-over-year growth, driven significantly by the acquisition of Apellis. The company achieved a core pharmaceutical revenue of $2 billion, up 18% year-over-year, with notable contributions from its growth portfolio, which generated approximately $1.3 billion, marking a 49% increase. Management raised the lower end of its non-GAAP diluted EPS guidance for the full year 2026 to between $12.20 and $13, indicating confidence in sustained growth and improved operational efficiency following the Apellis integration.

Reported metrics

MetricValueContext
Total Revenue $2.8 billion (positive) +11% YoY
Core Pharmaceutical Revenue $2 billion (positive) +18% YoY
SPINRAZA Revenue $461 million (positive) +23% YoY
SYFOVRE Revenue $191 million (positive) +27% YoY
Free Cash Flow $600 million
Non-GAAP Diluted EPS Guidance $12.20 - $13 (positive)

Guidance from management

Biogen is on track to deliver top-line growth for the first time in several years and has raised its non-GAAP diluted EPS guidance for 2026 to between $12.20 and $13, reflecting confidence in operational improvements and synergy capture from the Apellis acquisition.

What management said

Apologies, and thank you, Phil. So, taking a step back, we do recognize and acknowledge that lupus is a highly heterogeneous disease. We’ve examined previous trials — and we have extensively implemented multiple strategies in order to optimize the outcomes. I’ve talked about those before; and just to name a few. The steroid tapering, control of background standard of care meds. So there isn’t really anything new that...
— Priya Singhal, Q3 FY2026 earnings call
Thank you, Brian. Taking a step back, my view is that interferon gene signature is something we expect to be high among SLE patients generally, and the literature backs that up as well. And truly, looking at baseline, we aren't aware of any differences between LiLAC and TOPAZ-1 and 2 when it comes to interferon gene signature. We will only find out later, once we examine the data, and these are areas we will be looki...
— Priya Singhal, Q3 FY2026 earnings call

What analysts pressed on

Analysts expressed concerns regarding the potential drop in revenue from Q3 to Q4, questioning the sustainability of the growth trajectory. There were also inquiries about the competitive landscape for new product launches and the effectiveness of market education efforts for SYFOVRE and EMPAVELI.

Main topics on the call

Read the full Biogen Inc. transcript (Q3 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

About Biogen Inc.

Biogen Inc. (BIIB) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NASDAQ and is based in US. EarningsCalls.dev maintains a full-text archive of its earnings call transcripts — 28 calls on record spanning January 30, 2020 to October 28, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics. The latest calls are free to read; the full history is available through our REST API.

Earnings Call History

EarningsCalls.dev has 28 Biogen Inc. earnings call transcripts on record, spanning January 30, 2020 to October 28, 2026. Based on this history, Biogen Inc. reports quarterly. The most recent call on file is dated October 28, 2026. The full list is below — each row opens the transcript.

Ticker
BIIB
Exchange
NASDAQ
Country
US
Sector
Health Care
Industry
Biotechnology
Calls on record
28
First call
January 30, 2020
Most recent
October 28, 2026
Reporting cadence
quarterly
Quarter Date
Q3 FY2026 Oct 28, 2026 Read transcript →
Q2 FY2026 Jul 29, 2026 Read transcript →
Q1 FY2026 Apr 29, 2026 Read transcript →
Q4 FY2025 Feb 6, 2026 Read transcript →
Q3 FY2025 Oct 30, 2025 Read transcript →
Q2 FY2025 Jul 31, 2025 Read transcript →
Q1 FY2025 May 1, 2025 Read transcript →
Q4 FY2024 Feb 12, 2025 Read transcript →
Q3 FY2024 Oct 30, 2024 Read transcript →
Q2 FY2024 Aug 1, 2024 Read transcript →
Q1 FY2024 Apr 24, 2024 Read transcript →
Q4 FY2023 Feb 13, 2024 Read transcript →
Q3 FY2023 Nov 8, 2023 Read transcript →
Q2 FY2023 Jul 25, 2023 Read transcript →
Q1 FY2023 Apr 25, 2023 Read transcript →
Q4 FY2022 Feb 15, 2023 Read transcript →
Q3 FY2022 Oct 25, 2022 Read transcript →
Q2 FY2022 Jul 20, 2022 Read transcript →
Q1 FY2022 May 3, 2022 Read transcript →
Q4 FY2021 Feb 3, 2022 Read transcript →
Q3 FY2021 Oct 20, 2021 Read transcript →
Q2 FY2021 Jul 22, 2021 Read transcript →
Q1 FY2021 Apr 22, 2021 Read transcript →
Q4 FY2020 Feb 3, 2021 Read transcript →
Q3 FY2020 Oct 21, 2020 Read transcript →
Q2 FY2020 Jul 22, 2020 Read transcript →
Q1 FY2020 Apr 22, 2020 Read transcript →
Q4 FY2019 Jan 30, 2020 Read transcript →